Trial Profile
Multicenter Clinical Study on the Safety and Efficacy of Nilotinib Discontinuation in Patients with Chronic Myelogenous Leukemia-Chronic Phase and Complete Molecular Response.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2018
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STAT2
- 14 Sep 2018 Status changed from active, no longer recruiting to completed.
- 25 Jun 2017 Results of association of nilotinib trough concentraion and liver dysfunction data from two studies (STAT1 and STAT2) presented at the 22nd Congress of the European Haematology Association
- 06 Dec 2016 Results of subgroup analysis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.